Loading…
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $330M | $39M | $19M | $40M | 8.7% | 12.5% | 12.5% |
| 2024 | $293M | $32M | $17M | $38M | 7.8% | 6.8% | -40.5% |
| 2023 | $274M | $26M | $29M | $33M | 14.7% | 11.2% | -259.6% |
| 2022 | $247M | $2M | $-18M | $3M | -14.7% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 246.78 | 274.42 | 292.98 | 329.52 |
| Operating Revenue | - | 246.78 | 274.42 | 292.98 | 329.52 |
| Cost Of Revenue | - | 70.81 | 79.29 | 76.30 | 79.38 |
| Gross Profit | - | 175.98 | 195.13 | 216.69 | 250.15 |
| Operating Expense | - | 188.73 | 177.09 | 194.51 | 220.87 |
| Research And Development | - | 7.09 | 7.82 | 8.83 | 8.48 |
| Selling General And Administration | - | 167.21 | 169.19 | 183.14 | 209.94 |
| Total Expenses | - | 259.54 | 256.38 | 270.80 | 300.24 |
| Operating Income | - | -12.76 | 18.04 | 22.18 | 29.28 |
| Total Operating Income As Reported | - | -12.76 | 18.04 | 22.18 | 29.28 |
| EBITDA | - | 1.75 | 26.46 | 32.37 | 39.02 |
| Normalized EBITDA | - | 1.75 | 26.46 | 32.37 | 39.02 |
| EBIT | - | -12.68 | 19.92 | 25.57 | 32.38 |
| Interest Income | - | 0.06 | 1.87 | 3.38 | 3.10 |
| Interest Expense | - | 2.79 | 4.15 | 2.08 | 1.04 |
| Net Interest Income | - | -2.73 | -2.27 | 1.30 | 2.06 |
| Other Non Operating Income Expenses | - | 0.01 | 0 | 0.01 | 0 |
| Other Income Expense | - | 0.01 | 0 | 0.01 | 0 |
| Interest Income Non Operating | - | 0.06 | 1.87 | 3.38 | 3.10 |
| Interest Expense Non Operating | - | 2.79 | 4.15 | 2.08 | 1.04 |
| Net Non Operating Interest Income Expense | - | -2.73 | -2.27 | 1.30 | 2.06 |
| Pretax Income | - | -15.47 | 15.77 | 23.49 | 31.34 |
| Tax Provision | - | 2.39 | -12.74 | 6.53 | 12.25 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -17.87 | 28.52 | 16.96 | 19.09 |
| Net Income From Continuing And Discontinued Operation | - | -17.87 | 28.52 | 16.96 | 19.09 |
| Net Income From Continuing Operation Net Minority Interest | - | -17.87 | 28.52 | 16.96 | 19.09 |
| Net Income | - | -17.87 | 28.52 | 16.96 | 19.09 |
| Net Income Common Stockholders | - | -17.87 | 28.52 | 16.96 | 19.09 |
| Net Income Including Noncontrolling Interests | - | -17.87 | 28.52 | 16.96 | 19.09 |
| Normalized Income | - | -17.87 | 28.52 | 16.96 | 19.09 |
| Diluted NI Availto Com Stockholders | - | -17.87 | 28.52 | 16.96 | 19.09 |
| Basic Average Shares | - | 20.07 | 22.93 | 23.88 | 22.87 |
| Diluted Average Shares | - | 20.07 | 23.18 | 24.14 | 23.30 |
| Reconciled Depreciation | - | 6.27 | 6.54 | 6.79 | 6.64 |
| Reconciled Cost Of Revenue | - | 78.97 | 72.83 | 72.04 | 75.18 |
| Depreciation Amortization Depletion Income Statement | - | 14.43 | 0.08 | 2.53 | 2.44 |
| Depreciation And Amortization In Income Statement | - | 14.43 | 0.08 | 2.53 | 2.44 |
| General And Administrative Expense | - | 60.80 | 62.07 | 71.14 | 88.70 |
| Other Gand A | - | 60.80 | 62.07 | 71.14 | 88.70 |
| Rent Expense Supplemental | - | 11.19 | 12.58 | 11.48 | 10.69 |
| Selling And Marketing Expense | - | 106.42 | 107.12 | 112.01 | 121.24 |
| Amortization | - | 14.43 | 0.08 | 2.53 | 2.44 |
| Amortization Of Intangibles Income Statement | - | 14.43 | 0.08 | 2.53 | 2.44 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tactile Systems Technology, Inc.this co. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| Altimmune, Inc. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| MiMedx Group, Inc. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Rigel Pharmaceuticals, Inc. | RIGL | $560M | 1.52 | 1.43 | 93.8% | 4.35 |
| Ironwood Pharmaceuticals, Inc. | IRWD |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $560M |
| 23.30 |
| -2.14 |
| -9.2% |
| 9.00 |
| Cytek Biosciences, Inc. | CTKB | $559M | -8.40 | 1.64 | -19.5% | -28.29 |
| Cerus Corporation | CERS | $559M | - | 8.70 | -24.3% | - |
| NeuroPace, Inc. | NPCE | $556M | -25.92 | 29.24 | -112.8% | -50.21 |
| Fulgent Genetics, Inc. | FLGT | $554M | -9.15 | 0.50 | -5.4% | -11.16 |
| Peer Median | - | -6.45 | 1.92 | -14.3% | -6.43 | |